» Articles » PMID: 39001551

A Probabilistic Approach to Estimate the Temporal Order of Pathway Mutations Accounting for Intra-Tumor Heterogeneity

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jul 13
PMID 39001551
Authors
Affiliations
Soon will be listed here.
Abstract

The development of cancer involves the accumulation of somatic mutations in several essential biological pathways. Delineating the temporal order of pathway mutations during tumorigenesis is crucial for comprehending the biological mechanisms underlying cancer development and identifying potential targets for therapeutic intervention. Several computational and statistical methods have been introduced for estimating the order of somatic mutations based on mutation profile data from a cohort of patients. However, one major issue of current methods is that they do not take into account intra-tumor heterogeneity (ITH), which limits their ability to accurately discern the order of pathway mutations. To address this problem, we propose PATOPAI, a probabilistic approach to estimate the temporal order of mutations at the pathway level by incorporating ITH information as well as pathway and functional annotation information of mutations. PATOPAI uses a maximum likelihood approach to estimate the probability of pathway mutational events occurring in a specific sequence, wherein it focuses on the orders that are consistent with the phylogenetic structure of the tumors. Applications to whole exome sequencing data from The Cancer Genome Atlas (TCGA) illustrate our method's ability to recover the temporal order of pathway mutations in several cancer types.

Citing Articles

Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.

Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).

PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.

References
1.
Collisson E, Bailey P, Chang D, Biankin A . Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(4):207-220. DOI: 10.1038/s41575-019-0109-y. View

2.
Chen W, Barszczyk A, Turlova E, Deurloo M, Liu B, Yang B . Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion. Oncotarget. 2015; 6(18):16321-40. PMC: 4599272. DOI: 10.18632/oncotarget.3872. View

3.
Gittleman H, Lim D, Kattan M, Chakravarti A, Gilbert M, Lassman A . An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro Oncol. 2017; 19(5):669-677. PMC: 5464437. DOI: 10.1093/neuonc/now208. View

4.
Schwartz R, Schaffer A . The evolution of tumour phylogenetics: principles and practice. Nat Rev Genet. 2017; 18(4):213-229. PMC: 5886015. DOI: 10.1038/nrg.2016.170. View

5.
Deshwar A, Vembu S, Yung C, Jang G, Stein L, Morris Q . PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. 2015; 16:35. PMC: 4359439. DOI: 10.1186/s13059-015-0602-8. View